NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications

Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care

Related Keywords

United States ,American ,Brandon Owens ,Kate Mcneil ,Porter Novelli ,Pierre Louis Germain ,Linkedin ,French Financial Markets Authority Autorit ,Communications Department ,Twitter ,Investor Relations Department ,Nasdaq ,Exchange Commission ,Pharmaengine Inc ,Euronext ,American Society ,Clinical Oncology ,Laurent Levy ,Comprehensive Approach ,Locally Advanced Head ,Neck Cancer Inclusive ,Concurrent Chemoradiation ,Locally Advanced ,Recurrent Head ,Neck Squamous Cell ,Neoadjuvant Setting ,Unresectable Rectal ,Private Securities Litigation Reform Act ,Annual Report ,French Financial Markets Authority ,Des March ,Half Year Financial Report ,Investor Relations ,Louis Germain ,Nanobiotix ,Data ,Eaturing ,Nbtxr3 ,Plus ,Chemoradiation ,Preoperative ,Setting ,Support ,Road ,Applicability ,Head ,Neck ,Dancer ,Mother ,Olid ,Humor ,Indications ,